New cancer-killing virus tested in study
Years ago, researchers discovered that some viruses kill cancer It can have potential. Now it’s one The patients in clinical First stage study like that virus managed, malicious Tumors are shrinking let and Cancer treatment Goal.
Cancer research is evolving and evolving. Experts have now taken an important step. Oncolytic virus has been used in animal experiments to reduce the size of various carcinomas. Now it is being tested on cancer patients.
The immune system is stimulated
The Cancer Hospital of City of Hope National Medical Center in Duarte, Los Angeles County, California, USA, and Imogen Ltd., an Australian biotechnology company, have announced that a new lethal cancer virus has been administered to the first patient in a phase I clinical trial. .
to me message The clinic has previously shown in preclinical laboratory and animal models that City of Hope’s oncolytic virus CF33-hNIS, also known as vaxinia, shrinks colon, lung, breast, ovarian and pancreatic tumors.
“Our previous research showed that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to respond better to other immunotherapies, including checkpoint inhibitors.”to explain Dr.. Daning Li Phone City of Hope.
“Now is the time to ramp up the power of immunotherapy, and we believe CF33-hNIS has the potential to improve outcomes for our patients battling cancer.”
Immunotherapy becomes more effective
Oncogenic viral therapy becomes possible once naturally occurring viruses are genetically modified to infect, replicate, and kill cancer cells while preserving healthy cells.
While immune checkpoint inhibitors have been effective in certain types of cancer, patients often relapse and eventually become unresponsive to this type of treatment or develop resistance to this treatment.
Early research shows that oncolytic viruses can boost a person’s immune system and increase PD-L1 levels in tumors, making immunotherapy more effective against cancer.
Investigation of study centers in the USA and Australia
A phase I multicenter study begins with administration of low-dose CF33-hNIS in cancer patients with metastatic or advanced solid tumors who have received at least two previous lines of standard therapy. The test treatment is done either by injecting directly into the tumor or intravenously.
Once patients in the monotherapy group have been treated with the lowest doses of CF33-hNIS and demonstrated their acceptable safety, some of the new study participants will receive experimental neoplastic virus in combination with pimbrolizumab immunotherapy, an engineered antibody that boosts the immune system’s ability to fight cancer-causing cells.
The study aims to enroll 100 cancer patients at nearly ten study centers in the United States and Australia.
According to the information, City of Hope has licensed the patent rights to CF33 exclusively to Imugene Limited, a company that develops new treatments that activate the immune system against cancer. Imugene has named CF33-hNIS Vaxinia.
The study is expected to last for two years
“Interestingly, the same properties that make cancer cells resistant to chemotherapy or radiotherapy actually enhance the success of oncolytic viruses such as CF33-hNIS.”explains the lead developer of the genetically modified virus, Dr. Yuman Fong Phone City of Hope.
“We hope to capitalize on the promise of virology and immunotherapy to treat a variety of deadly cancers.”
The clinical study is expected to last approximately 24 months. (ad)
Author and source information
This text complies with the specifications of the medical literature, clinical guidelines, and current studies and has been verified by medical professionals.
important note:
This article contains general advice only and should not be used for self-diagnosis or treatment. It cannot replace a visit to the doctor.
